-
Je něco špatně v tomto záznamu ?
Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study
MP. Jacobson, L. Pazdera, P. Bhatia, T. Grinnell, H. Cheng, D. Blum, . ,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem
NLK
BioMedCentral
od 2001-12-01
BioMedCentral Open Access
od 2001
Directory of Open Access Journals
od 2001
Free Medical Journals
od 2001
PubMed Central
od 2001
Europe PubMed Central
od 2001
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2001-01-01
Open Access Digital Library
od 2001-01-01
Open Access Digital Library
od 2001-01-01
Medline Complete (EBSCOhost)
od 2001-12-18
Health & Medicine (ProQuest)
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2001
Springer Nature OA/Free Journals
od 2001-12-01
- MeSH
- antikonvulziva terapeutické užití MeSH
- dibenzazepiny terapeutické užití MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- epilepsie parciální farmakoterapie MeSH
- Kaplanův-Meierův odhad MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- senioři MeSH
- výsledek terapie MeSH
- záchvaty farmakoterapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: Eslicarbazepine acetate (ESL, Aptiom®) is a once-daily (QD) anticonvulsant, approved as adjunctive treatment of partial-onset seizures (POS). It is extensively converted after oral administration to eslicarbazepine, and is believed to exert its effect through inhibition of voltage-gated sodium channels. The possible role of ESL as monotherapy to treat POS has not yet been established. METHODS: This study was an 18-week, multicenter, randomized double-blind trial of gradual conversion to ESL monotherapy in adults with POS not well controlled by 1-2 antiepileptic drugs (AEDs), using historical data as the control. The study comprised an 8-week baseline period, a 2-week titration period, a 6-week AED conversion period, a 10-week monotherapy period, and either a 1-week taper period or optional entry to an open-label extension study. The primary endpoint compared the Kaplan-Meier (KM)-estimated 112-day exit rate with a threshold value calculated from the historical controls. RESULTS: There were 172 randomized patients; 154 (90%) entered the AED conversion period and 121 (70%) completed the study. The KM-estimated exit rates [confidence interval (CI)] were 15.6% [8.1-28.7%] for ESL 1200 mg, and 12.8% [7.5-21.5%] for ESL 1600 mg. The upper limits of the 95% CI KM-estimates were below the pre-specified threshold for historical control of 65.3%, indicating that ESL was efficacious in reducing seizure-related exits, compared with historical control. During the 18-week double-blind treatment period, median reductions in standardized seizure frequency occurred with ESL 1200 mg (36.1%) and ESL 1600 mg (47.5%). The responder rates (a 50% or greater reduction in seizure frequency from baseline) during the 18-week double-blind period and the monotherapy period, respectively, were 35.2% and 38.9% for ESL 1200 mg, and 46.0% and 46.0% for ESL 1600 mg. The overall adverse event profile was consistent with the known safety profile of ESL. CONCLUSIONS: These findings indicate that ESL monotherapy (1200 and 1600 mg QD) was efficacious and well tolerated in this study. TRIAL REGISTRATION: NCT01091662 ; EudraCT No. 2010-018684-42.
CTC Rychnov nad Kněznou s r o Rychnov nad Kneznou Czech Republic
Department of Neurology Temple University School of Medicine Philadelphia PA USA
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16020875
- 003
- CZ-PrNML
- 005
- 20160726095417.0
- 007
- ta
- 008
- 160722s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12883-015-0305-5 $2 doi
- 024 7_
- $a 10.1186/s12883-015-0305-5 $2 doi
- 035 __
- $a (PubMed)25880756
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Jacobson, Mercedes P $u Department of Neurology, Temple University School of Medicine, Philadelphia, PA, USA. mercedes.jacobson@tuhs.temple.edu.
- 245 10
- $a Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study / $c MP. Jacobson, L. Pazdera, P. Bhatia, T. Grinnell, H. Cheng, D. Blum, . ,
- 520 9_
- $a BACKGROUND: Eslicarbazepine acetate (ESL, Aptiom®) is a once-daily (QD) anticonvulsant, approved as adjunctive treatment of partial-onset seizures (POS). It is extensively converted after oral administration to eslicarbazepine, and is believed to exert its effect through inhibition of voltage-gated sodium channels. The possible role of ESL as monotherapy to treat POS has not yet been established. METHODS: This study was an 18-week, multicenter, randomized double-blind trial of gradual conversion to ESL monotherapy in adults with POS not well controlled by 1-2 antiepileptic drugs (AEDs), using historical data as the control. The study comprised an 8-week baseline period, a 2-week titration period, a 6-week AED conversion period, a 10-week monotherapy period, and either a 1-week taper period or optional entry to an open-label extension study. The primary endpoint compared the Kaplan-Meier (KM)-estimated 112-day exit rate with a threshold value calculated from the historical controls. RESULTS: There were 172 randomized patients; 154 (90%) entered the AED conversion period and 121 (70%) completed the study. The KM-estimated exit rates [confidence interval (CI)] were 15.6% [8.1-28.7%] for ESL 1200 mg, and 12.8% [7.5-21.5%] for ESL 1600 mg. The upper limits of the 95% CI KM-estimates were below the pre-specified threshold for historical control of 65.3%, indicating that ESL was efficacious in reducing seizure-related exits, compared with historical control. During the 18-week double-blind treatment period, median reductions in standardized seizure frequency occurred with ESL 1200 mg (36.1%) and ESL 1600 mg (47.5%). The responder rates (a 50% or greater reduction in seizure frequency from baseline) during the 18-week double-blind period and the monotherapy period, respectively, were 35.2% and 38.9% for ESL 1200 mg, and 46.0% and 46.0% for ESL 1600 mg. The overall adverse event profile was consistent with the known safety profile of ESL. CONCLUSIONS: These findings indicate that ESL monotherapy (1200 and 1600 mg QD) was efficacious and well tolerated in this study. TRIAL REGISTRATION: NCT01091662 ; EudraCT No. 2010-018684-42.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antikonvulziva $x terapeutické užití $7 D000927
- 650 _2
- $a dibenzazepiny $x terapeutické užití $7 D003984
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a epilepsie parciální $x farmakoterapie $7 D004828
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Kaplanův-Meierův odhad $7 D053208
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a záchvaty $x farmakoterapie $7 D012640
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pazdera, Ladislav $u CTC Rychnov nad Kněznou s.r.o, Rychnov nad Kneznou, Czech Republic. pazdera@neurol.cz.
- 700 1_
- $a Bhatia, Perminder $u Neuro-Pain Medical Center, Fresno, CA, USA. neuro736@gmail.com.
- 700 1_
- $a Grinnell, Todd $u Sunovion Pharmaceuticals Inc., Marlborough, MA, USA. todd.grinnell@sunovion.com.
- 700 1_
- $a Cheng, Hailong $u Sunovion Pharmaceuticals Inc., Marlborough, MA, USA. hailong.cheng@sunovion.com.
- 700 1_
- $a Blum, David $u Sunovion Pharmaceuticals Inc., Marlborough, MA, USA. david.blum@sunovion.com.
- 700 1_
- $a ,
- 773 0_
- $w MED00008195 $t BMC neurology $x 1471-2377 $g Roč. 15, č. - (2015), s. 46
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25880756 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20160726095636 $b ABA008
- 999 __
- $a ok $b bmc $g 1155545 $s 945403
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 15 $c - $d 46 $e 20150328 $i 1471-2377 $m BMC neurology $n BMC Neurol $x MED00008195
- LZP __
- $a Pubmed-20160722